Shukra Pharmaceuticals is a pharmaceutical manufacturer that spent three decades building a WHO-GMP-certified formulations business from a single campus in Gujarat, then in 2025-26 made a sudden leap into medical technology distribution and healthcare services - a pivot executed not through internal R&D but by rapidly assembling a network of distribution authorisations, government service agreements, and two new subsidiaries. The recurring approach is visible in both eras: the company identifies a set of customers with specific procurement needs - whether global merchant exporters buying generic drugs or Indian defence hospitals buying surgical robots - and positions itself as the compliant, technically credible middleman who can develop, register, or represent the product and deliver it. # Business segments Two engines at different stages - a mature pharmaceutical manufacturing and export business built on in-house formulation development, and a newly assembled medical technology distribution and services platform that went from zero to a full operating segment in under six months. ## 1. Pharmaceutical manufacturing and exports: the formulations engine the company was built on **A single-campus manufacturer that develops and ships generic drugs in multiple dosage forms to over 25 countries, earning its place through plant registrations and long-standing merchant-export relationships rather than proprietary molecules.** - **WHO-GMP since 1998 as the entry ticket** - the plant has held WHO-GMP certification for over 25 years, which is what allows its products to be registered in countries like Kenya, Nigeria, Ghana, Uganda, Sierra Leone, Congo, Yemen, Cambodia, and Myanmar, creating a regulatory moat that competitors without those registrations cannot easily cross. - **Direct exports plus a merchant-export layer** - the company sells directly to buyers in Australia, the UK, Sri Lanka, Kenya, Uganda, and several other markets, but also supplies merchant exporters based in the UK, Denmark, Australia, and Singapore who then on-ship to an additional dozen countries including Senegal, Ghana, Papua New Guinea, Ukraine, Poland, and Sudan. - **Contract manufacturing for global pharma companies** - it develops and manufactures drugs for reputed pharmaceutical companies from around the world, treating these relationships as strategic partnerships that run from formulation development through to scheduled delivery, which diversifies its customer base beyond its own-label sales. - **A broad but generic portfolio** - the product range spans over 20 therapeutic categories from antibiotics and anti-malarials to antidepressants and corticosteroids, meaning the company is not dependent on any single drug class, though it also means it competes in a crowded Indian industry with more than 20,000 manufacturing units. ## 2. Shukra MedTech: a distribution-and-services platform assembled for government healthcare tenders **A newly created segment that does not manufacture anything itself but instead holds distribution rights, OEM authorisations, and a government PSU service agreement, all aimed at supplying medical devices and managing healthcare projects for India's defence and public-health institutions.** - **Built through authorisations, not factories** - between July and December 2025, the company secured distribution or representation agreements with manufacturers of surgical instruments, orthopaedic implants, ICU ventilators, laparoscopy sets, and diagnostic equipment, plus exclusive or non-exclusive rights to quote and supply for specific government tender channels like DGAFMS, ESIC hospitals, UPMSL, and GMSCL. - **A government PSU as the services backbone** - a Service Agreement with APITCO Limited (a Government of India PSU) positions the company as a healthcare project management consultant and training provider for government healthcare assignments, with each project governed by defined SLAs covering scope, timelines, and deliverables. - **Robotics as the aspirational layer** - through its 85%-owned subsidiary Shukra Robotics, the company signed an MOU with Borns Medical Robotics of the USA to explore commercialising AI-enabled soft-tissue surgical robotic systems across India and five neighbouring countries, and separately holds an authorisation from Meril Healthcare to represent robotic-assisted orthopaedic surgery systems for DGAFMS tenders. - **Four new branch offices to chase tenders** - the company opened offices in Mumbai, Gurgaon, Bangalore, and Kolkata in mid-2025 specifically to participate in government, semi-government, and private-sector tenders and to build relationships with institutional clients and procurement agencies. # Group structure and partners **A promoter-led public company that operated without subsidiaries for most of its history, then incorporated two 85%-owned subsidiaries in late 2025 as vehicles for its MedTech ambitions, while its commercial partnerships span pharmaceutical merchant exporters and a rapidly assembled network of medical-device OEMs.** - **Two new subsidiaries for the new segment** - Shukra Healthtech Private Limited (incorporated October 2025) and Shukra Robotics Private Limited (incorporated November 2025) are both 85% held by Shukra Pharmaceuticals, with the robotics subsidiary designated as the vehicle for the Borns Medical Robotics collaboration. - **Promoter group with surgical-industry ties** - the company is led by Managing Director Dakshesh Rameshchandra Shah, and promoter-group entities include Navkar Surgical Gujarat Limited, suggesting domain familiarity with the surgical and medical-device space the company is now entering. - **Merchant-export partners extend geographic reach** - UK, Denmark, Australia, and Singapore-based buyers act as indirect export channels, taking Shukra-manufactured products into markets the company does not serve directly, including NGO tender channels in Africa and the Pacific Islands.